Table 2:

Active genomically-matched trials in biliary tract cancers

Target	Therapy	Dedicated Trial or Basket	Biomarker Selection	Phase	Clinical Trial Registry #
ERK1/2	Ulixertinib	Basket	KRAS, NRAS, HRAS, BRAF (non-V600), MEK, and ERK Mutations	I	NCT04145297
FGFR	Infigratinib	CCA	FGFR2 Fusions/Translocations	III	NCT03773302
FGFR	Infigratinib	CCA	FGFR2 Mutation	II	NCT02150967
FGFR	Infigratinib	Basket	FGFR1–3 Fusions or Amplifications	II	NCT04233567
FGFR	Futibatinib	CCA	FGFR2 Rearrangement	III	NCT04093362
FGFR	Pemigatinib	CCA	FGFR2 Rearrangement	III	NCT03656536
FGFR	Derazantinib	CCA	FGFR2 Fusion, Mutation, or Amplification	II	NCT03230318
FGFR	RLY-4008	Basket	FGFR2 Fusion, Mutation, or Amplification	I	NCT04526106
FGFR	Pemigatinib	Basket	FGF/FGFR Alterations	I/II	NCT02393248
HER2	Zanidatamab	BTC	HER2 Amplification	II	NCT04466891
HER2	Tucatinib + Trastuzumab	Basket	HER2 Amplification or Overexpression	I/II	NCT04430738
HER2	Tucatinib + Trastuzumab	Basket	HER2 Mutation	II	NCT04579380
HER2	Trastuzumab deruxtecan	Basket	HER2 Expressing	II	NCT04482309
HER2	RC48-ADC	BTC	HER2 Overexpression	II	NCT04329429
IDH1	LY3410738	Basket	IDH1_R132 Mutation	I	NCT04521686
IDH1, FGFR	Ivosidenib, Pemigatinib	CCA	IDH1_R132 Mutation, FGFR Alterations	I	NCT04088188
MEK	Trametinib	BTC	KRAS Mutation	II	NCT04566133
NTRK	Entrectinib	Basket	NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)	II	NCT02568267
PARP	Olaparib	Basket	IDH1/2 Mutations	II	NCT03212274
PARP	Olaparib	BTC	DDR Pathway Mutations (Somatic or Germline)	II	NCT04042831
PARP	Niraparib	Basket	DDR Pathway Mutations	II	NCT03207347
PARP, ATR	Olaparib + Cerelasertib	Basket	IDH1/2 Mutations	II	NCT03878095

Table 2: This table highlights ongoing genomically-matched clinical trials in biliary tract cancers [9].

BTC, biliary tract cancers; CCA, cholangiocarcinoma.